MEI PHARMA INC (MEIP) Stock Fundamental Analysis
USA - NASDAQ:MEIP - US55279B3015 - Common Stock
3.07 USD
+0.29 (+10.43%)
3.16 USD
+0.09 (+2.93%)
Taking everything into account, MEIP scores 4 out of 10 in our fundamental rating. MEIP was compared to 531 industry peers in the Biotechnology industry. MEIP has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, MEIP is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year MEIP was profitable.
In the past year MEIP has reported a negative cash flow from operations.
MEIP had negative earnings in 4 of the past 5 years.
In the past 5 years MEIP reported 4 times negative operating cash flow.
1.2 Ratios
The Return On Assets of MEIP (-152.38%) is worse than 85.95% of its industry peers.
MEIP has a worse Return On Equity (-162.03%) than 63.77% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -152.38% | ||
| ROE | -162.03% | ||
| ROIC | N/A |
ROA(3y)-4.67%
ROA(5y)-12.05%
ROE(3y)-59.83%
ROE(5y)-64.83%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MEIP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
MEIP does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MEIP has less shares outstanding
The number of shares outstanding for MEIP has been increased compared to 5 years ago.
MEIP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 19.34 indicates that MEIP is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 19.34, MEIP belongs to the best of the industry, outperforming 92.05% of the companies in the same industry.
There is no outstanding debt for MEIP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 19.34 |
ROIC/WACCN/A
WACC9.66%
2.3 Liquidity
MEIP has a Current Ratio of 16.78. This indicates that MEIP is financially healthy and has no problem in meeting its short term obligations.
MEIP has a better Current ratio (16.78) than 92.05% of its industry peers.
MEIP has a Quick Ratio of 16.78. This indicates that MEIP is financially healthy and has no problem in meeting its short term obligations.
MEIP has a better Quick ratio (16.78) than 92.05% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 16.78 | ||
| Quick Ratio | 16.78 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 157.67% over the past year.
Looking at the last year, MEIP shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
The Revenue has been growing by 67.72% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)157.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%71.81%
Revenue 1Y (TTM)-100%
Revenue growth 3Y23.34%
Revenue growth 5Y67.72%
Sales Q2Q%N/A
3.2 Future
MEIP is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -67.16% yearly.
Based on estimates for the next years, MEIP will show a very strong growth in Revenue. The Revenue will grow by 85.04% on average per year.
EPS Next Y-339.91%
EPS Next 2Y-84.86%
EPS Next 3Y-37.44%
EPS Next 5Y-67.16%
Revenue Next Year-100%
Revenue Next 2Y-38.12%
Revenue Next 3Y-27.39%
Revenue Next 5Y85.04%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 1.15, the valuation of MEIP can be described as very cheap.
Compared to the rest of the industry, the Price/Earnings ratio of MEIP indicates a rather cheap valuation: MEIP is cheaper than 99.45% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 26.06. MEIP is valued rather cheaply when compared to this.
The Forward Price/Earnings Ratio is negative for MEIP. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1.15 | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
MEIP's earnings are expected to decrease with -37.44% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-84.86%
EPS Next 3Y-37.44%
5. Dividend
5.1 Amount
No dividends for MEIP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
3.07
+0.29 (+10.43%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst OwnersN/A
Inst Owner Change11.88%
Ins OwnersN/A
Ins Owner Change0%
Market Cap100.82M
Revenue(TTM)N/A
Net Income(TTM)-31.66M
Analysts43.33
Price Target6.12 (99.35%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend1.75
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1.15 | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 5.16 | ||
| P/tB | 5.16 | ||
| EV/EBITDA | N/A |
EPS(TTM)2.67
EY86.97%
EPS(NY)-3.78
Fwd EYN/A
FCF(TTM)-1.11
FCFYN/A
OCF(TTM)-1.11
OCFYN/A
SpS0
BVpS0.6
TBVpS0.6
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -152.38% | ||
| ROE | -162.03% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-4.67%
ROA(5y)-12.05%
ROE(3y)-59.83%
ROE(5y)-64.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 0% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 16.78 | ||
| Quick Ratio | 16.78 | ||
| Altman-Z | 19.34 |
F-Score2
WACC9.66%
ROIC/WACCN/A
Cap/Depr(3y)52.51%
Cap/Depr(5y)242.29%
Cap/Sales(3y)0.42%
Cap/Sales(5y)1.3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)157.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%71.81%
EPS Next Y-339.91%
EPS Next 2Y-84.86%
EPS Next 3Y-37.44%
EPS Next 5Y-67.16%
Revenue 1Y (TTM)-100%
Revenue growth 3Y23.34%
Revenue growth 5Y67.72%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-38.12%
Revenue Next 3Y-27.39%
Revenue Next 5Y85.04%
EBIT growth 1Y-200.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y36.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.82%
OCF growth 3YN/A
OCF growth 5YN/A
MEI PHARMA INC / MEIP FAQ
What is the fundamental rating for MEIP stock?
ChartMill assigns a fundamental rating of 4 / 10 to MEIP.
What is the valuation status of MEI PHARMA INC (MEIP) stock?
ChartMill assigns a valuation rating of 2 / 10 to MEI PHARMA INC (MEIP). This can be considered as Overvalued.
What is the profitability of MEIP stock?
MEI PHARMA INC (MEIP) has a profitability rating of 0 / 10.
What are the PE and PB ratios of MEI PHARMA INC (MEIP) stock?
The Price/Earnings (PE) ratio for MEI PHARMA INC (MEIP) is 1.15 and the Price/Book (PB) ratio is 5.16.
What is the financial health of MEI PHARMA INC (MEIP) stock?
The financial health rating of MEI PHARMA INC (MEIP) is 9 / 10.